MorphoSys Dirección

Dirección controles de criterios 4/4

Actualmente no disponemos de información suficiente sobre el CEO.

Información clave

Jean-Paul Kress

Chief Executive Officer (CEO)

€4.8m

Compensación total

Porcentaje del salario del CEO	18.1%
Permanencia del CEO	4.8yrs
Participación del CEO	n/a
Permanencia media de la dirección	2.9yrs
Promedio de permanencia en la Junta Directiva	7.8yrs

Actualizaciones recientes de la dirección

Recent updates

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de Jean-Paul Kress en comparación con los beneficios de MorphoSys?
Fecha	Compensación total	Salario	Ingresos de la empresa
Mar 31 2024	n/a	n/a	-€469m
Dec 31 2023	€5m	€864k	-€190m
Sep 30 2023	n/a	n/a	€104m
Jun 30 2023	n/a	n/a	€100m
Mar 31 2023	n/a	n/a	-€61m
Dec 31 2022	€5m	€797k	-€151m
Sep 30 2022	n/a	n/a	-€861m
Jun 30 2022	n/a	n/a	-€851m
Mar 31 2022	n/a	n/a	-€596m
Dec 31 2021	€2m	€770k	-€514m
Sep 30 2021	n/a	n/a	-€150m
Jun 30 2021	n/a	n/a	-€103m
Mar 31 2021	n/a	n/a	-€177m
Dec 31 2020	€3m	€723k	€98m
Sep 30 2020	n/a	n/a	€64m
Jun 30 2020	n/a	n/a	€105m
Mar 31 2020	n/a	n/a	€153m
Dec 31 2019	€4m	€233k	-€103m

Compensación vs. Mercado: La compensación total ($USD5.10M) de Jean-Paul está en línea con el promedio de empresas de tamaño similar en el mercado US ($USD6.57M).

Compensación vs. Ingresos: La compensación de Jean-Paul ha sido consistente con los resultados de la empresa en el último año.

CEO

Jean-Paul Kress (59 yo)

4.8yrs

Permanencia

€4,764,900

Compensación

Dr. Jean-Paul Kress, M.D. has been the Chief Executive Officer of MorphoSys AG since September 1, 2019 and has been its Management Board Member since 2019 and serves as its Chairman of Management Board and...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Jean-Paul Kress	Chairman of Management Board	4.8yrs	€4.76m	sin datos
Lucinda Crabtree	CFO & Member of Management Board	1.4yrs	€1.51m	sin datos
Charlotte Lohmann	Chief Legal and Human Resources Officer & Member of Management Board	4.4yrs	€1.10m	0.0036% € 97.1k
Klaus De Wall	Head of Accounting & Tax	no data	sin datos	sin datos
Margit Urban	Head of Discovery Alliances & Technologies	no data	sin datos	sin datos
Julia Neugebauer	Head of Investor Relations	no data	sin datos	sin datos
Barbara Krebs-Pohl	Chief Business Officer	no data	sin datos	sin datos
Günter Wellnhofer	Head of Technical Operations	no data	sin datos	sin datos
Harald Watzka	Head of Alliance Management	no data	sin datos	sin datos
Yen Ching Chua	Head of Clinical Operations	no data	sin datos	sin datos
Kathrin Tissot	Head of Business Team	no data	sin datos	sin datos
Thomas Biegi	Senior VP & Head of Corporate Affairs	less than a year	sin datos	sin datos

2.9yrs

Permanencia media

54yo

Promedio de edad

Equipo directivo experimentado: El equipo directivo de MOR se considera experimentado (2.8 años antigüedad media).

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Bruce Cheson	Member of Scientific Advisory Board	7.8yrs	sin datos	sin datos
Gunther Adolf	Member of Scientific Advisory Board	7.8yrs	sin datos	sin datos
Sergio Quezada	Member of Scientific Advisory Board	7.8yrs	sin datos	sin datos
Raymond Sweet	Member of Scientific Advisory Board	7.8yrs	sin datos	sin datos
Sharon Curran	Independent Member of Supervisory Board	5yrs	€92.60k	sin datos

7.8yrs

Permanencia media

Junta con experiencia: La junta directiva de MOR se considera experimentada (7.3 años de antigüedad promedio).

MorphoSys Dirección

Dirección controles de criterios 4/4

Información clave

Actualizaciones recientes de la dirección

MorphoSys AG Announces Board Changes

MorphoSys AG Announces Sung Lee, Chief Financial Officer Decided to Leave

MorphoSys AG Announces Executive Changes

MorphoSys AG Announces Supervisory Board Changes

MorphoSys AG Announces Management Changes

MorphoSys AG, Annual General Meeting, May 19, 2021

Recent updates

MorphoSys AG Announces Board Changes

Novartis Continues to Progress the Workstreams for Implementation of a Delisting of MorphoSys

Novartis Continues to Progress the Workstreams for Implementation of a Delisting of MorphoSys

MorphoSys: Hold Rating Until The Novartis Deal Closes

Novartis data42 AG entered into an agreement to make a voluntary public takeover offer to acquire MorphoSys AG (XTRA:MOR) for €2.3 billion.

Novartis data42 AG entered into an agreement to make a voluntary public takeover offer to acquire MorphoSys AG (XTRA:MOR) for €2.3 billion.

Novartis And MorphoSys Are A Perfect Match

Novartis Reportedly in Lead to Acquire MorphoSys

MorphoSys AG Provides Sales Guidance for the Financial Year 2024

MorphoSys: Positive Pelabresib Data Finally Unlocking Upside

MorphoSys AG to Report First Half, 2024 Results on Aug 07, 2024

MorphoSys AG has filed a Follow-on Equity Offering in the amount of €102.69582 million.

MorphoSys AG to Report Fiscal Year 2023 Results on Mar 13, 2024

MorphoSys AG’ Pelabresib Improves All Four Hallmarks of Myelofibrosis in Phase 3 MANIFEST-2 Study

MorphoSys AG Announces Strong Topline Results from the Phase 3 MANIFEST-2 Study Investigating Pelabresib

MorphoSys AG to Showcase Phase 3 MANIFEST-2 Data on Pelabresib in Myelofibrosis in Oral Presentation at 2023 ASH Annual Meeting

Morphosys AG Provides Earnings Guidance for the Year 2023

Zoetis Inc. (NYSE:ZTS) acquired adivo GmbH from founders, High-Tech Gründerfonds, the Swiss Occident Group AG and MorphoSys AG (XTRA:MOR).

MorphoSys Receives U.S. FDA Fast Track Designation for Tulmimetostat in Endometrial Cancer

MorphoSys AG Provides Earnings Guidance for the Year 2023

Morphosys Ag Provides Sales Guidance for the Financial Year 2023

MorphoSys AG Expects Topline Data from Phase 3 Study of Pelabresib in Myelofibrosis in Early 2024

MorphoSys AG Announces Sung Lee, Chief Financial Officer Decided to Leave

Morphosys Presents New Longer-Term Phase 2 Results on Pelabresib in Myelofibrosis, Including Potential Disease-Modifying Activity At Ash 2022

MorphoSys AG to Report Q3, 2023 Results on Nov 15, 2023

MorphoSys AG Presents Preliminary Results from Phase 1/2 Study of Tulmimetostat (CPI-0209)

Morphosys Ag Revises Monjuvi U.S. Net Product Sales Guidance for the Full Year of 2022

MorphoSys AG Announces Executive Changes

Morphosys Ag Updates Monjuvi U.S. Net Product Sales Guidance for the Year 2022

MorphoSys updates Q2 & FY22 guidance below prior provided levels

MorphoSys AG Confirms Financial Guidance for the Year 2022

MorphoSys AG Announces Supervisory Board Changes

MorphoSys May Not Recover From Adventurous Constellation Buyout

Sierra Oncology's Strong Data In Myelofibrosis Challenges MorphoSys And Incyte

MorphoSys Presents Latest Data from the Phase 2 Manifest Study Evaluating the Potential of Pelabresib in the Treatment of Myelofibrosis

MorphoSys and Incyte Announce Additional Real-World Evidence Results from RE-MIND2 Study of Tafasitamab (Monjuvi®) in Combination with Lenalidomide for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Health Canada Grants Marketing Authorization for Minjuvi® (Tafasitamab) in Combination with Lenalidomide for the Treatment of Adults with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

MorphoSys AG (XTRA:MOR) completed the acquisition of Constellation Pharmaceuticals, Inc. (NasdaqGS:CNST).

Incyte and MorphoSys Announce Positive CHMP Opinion for Tafasitamab in Combination with Lenalidomide for the Treatment of Adults with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Incyte and MorphoSys presents new three-year data for blood cancer therapy

MorphoSys to Present Data on Tafasitamab (Monjuvi(R)) at the 2021 ASCO Annual Meeting

Incyte and MorphoSys Announce First Patient Dosed in Phase 3 frontMIND Study Evaluating Tafasitamab Combination as a First-Line Treatment for Diffuse Large B-Cell Lymphoma

MorphoSys AG Reaffirms Group Financial Guidance for the Year 2021

MorphoSys reports Q1 results

I-Mab and MorphoSys Announce First Patient Dosed in U.S. Phase 1 Study of TJ210/MOR210 in Patients with Advanced Cancer

Incyte Corporation and MorphoSys AG Announce Acceptance by Health Canada of the New Drug Submission for Tafasitamab

MorphoSys AG Announces Management Changes

MorphoSys AG appoints Sangamo 's Sung Lee as new CFO

Morphosys and Incyte Announce the Acceptance of the Swissmedic Marketing Authorization Application for Tafasitamab

MorphoSys AG, Annual General Meeting, May 19, 2021

Incyte and MorphoSys AG Announces Data Evaluating Tafasitamab with and Without Lenalidomide in Combination with R-CHOP in Patients with DLBCL Presented At ASH 2020

MorphoSys AG (MOR) Investor Presentation - Slideshow

Morphosys' Licensee Announces Approval by the European Commission for Tremfya(R) (Guselkumab) for Treatment of Adults with Active Psoriatic Arthritis

MorphoSys Appoints Thomas Biegi as Vice President, Head of Corporate Communications

MorphoSys AG 2020 Q3 - Results - Earnings Call Presentation

Xencor, MorphoSys AG and Incyte Enter into Global Development Collaboration for Tafasitamab in Combination with Plamotamab

MorphoSys reports Q3 results

MorphoSys to Present Data on Tafasitamab at the ASH Virtual Annual Meeting and Exposition

MorphoSys AG Raises Financial Guidance for the Financial Year 2020

Jens Holstein Decides to Step Down as Member of the Morphosys AG's Management Board, Effective December 31, 2020

Análisis de compensación del CEO

CEO

Permanencia

Compensación

Equipo directivo

Permanencia media

Promedio de edad

Miembros de la Junta

Permanencia media